AstraZeneca’s Soliris® Approved in Malaysia for Treatment of Rare Neurological Autoimmune Diseases and Severe Blood Disorders
Soliris®: Targeting of Complement System to Improve Clinical Outcomes in Rare Disease Petaling Jaya, 12 March 2026 – AstraZeneca, a global, science-led biopharmaceutical company, has made available its treatment, Soliris®, in Malaysia as part of its ongoing commitment to support patients living with rare disease worldwide. Soliris® marks a significant treatment advancement, having already contributed […]










